{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:23:16Z","timestamp":1765887796926},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T00:00:00Z","timestamp":1459382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T00:00:00Z","timestamp":1459382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Serum complement C3 levels are closely associated with obesity and related metabolic disorders. This study aimed to investigate the association between serum complement C3 levels with non-alcoholic fatty liver disease (NAFLD). A cross-sectional study was performed among adults who took their annual health examinations at Zhenhai Lianhua Hospital, Ningbo, China during 2014. We included 7540 participants (5069 men and 2471 women) in this study. NAFLD patients had higher serum complement C3 levels (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and these levels were positively associated with both NAFLD prevalence and severity (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). The above association remains true among lean and metabolic syndrome-free participants. Multivariable regression analysis showed that serum complement C3 was independently associated with risk for NAFLD (OR\u2009=\u20095.231; 95% CI: 3.169\u20138.635). Serum complement C3 level is positively associated with prevalence and severity of NAFLD and this association is independent of obesity and metabolic syndrome.<\/jats:p>","DOI":"10.1038\/srep23279","type":"journal-article","created":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T09:02:07Z","timestamp":1459414927000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Serum complement C3 levels are associated with nonalcoholic fatty liver disease independently of metabolic features in Chinese population"],"prefix":"10.1038","volume":"6","author":[{"given":"Chengfu","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaohui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,31]]},"reference":[{"key":"BFsrep23279_CR1","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","volume":"142","author":"N Chalasani","year":"2012","unstructured":"Chalasani, N. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases and American College of Gastroenterology. Gastroenterology 142, 1592\u20131609 (2012).","journal-title":"Gastroenterology"},{"key":"BFsrep23279_CR2","doi-asserted-by":"publisher","first-page":"g4596","DOI":"10.1136\/bmj.g4596","volume":"349","author":"N Sattar","year":"2014","unstructured":"Sattar, N., Forrest, E. & Preiss, D. Non-alcoholic fatty liver disease. BMJ 349, g4596 (2014).","journal-title":"BMJ"},{"key":"BFsrep23279_CR3","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/hep.23594","volume":"51","author":"BQ Starley","year":"2010","unstructured":"Starley, B. Q., Calcagno, C. J. & Harrison, S. A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51, 1820\u20131832 (2010).","journal-title":"Hepatology"},{"key":"BFsrep23279_CR4","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1053\/j.gastro.2006.03.019","volume":"130","author":"TS Church","year":"2006","unstructured":"Church, T. S. et al. Association of cardiorespiratory fitness, body mass index and waist circumference to nonalcoholic fatty liver disease. Gastroenterology 130, 2023\u20132030 (2006).","journal-title":"Gastroenterology"},{"key":"BFsrep23279_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3164\/jcbn.08-269","volume":"45","author":"K Omagari","year":"2009","unstructured":"Omagari, K. et al. Predictive factors for the development or regression of fatty liver in Japanese adults. Journal of clinical biochemistry and nutrition 45, 56 (2009).","journal-title":"Journal of clinical biochemistry and nutrition"},{"key":"BFsrep23279_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00535-012-0650-8","volume":"48","author":"T Miyake","year":"2013","unstructured":"Miyake, T. et al. Body mass index is the most useful predictive factor for the onset of nonalcoholic fatty liver disease: a community-based retrospective longitudinal cohort study. Journal of gastroenterology 48, 413\u2013422 (2013).","journal-title":"Journal of gastroenterology"},{"key":"BFsrep23279_CR7","doi-asserted-by":"crossref","unstructured":"Peng, L., Wang, J. & Li, F. Weight reduction for non-alcoholic fatty liver disease. Cochrane Database Syst Rev, CD003619 (2011).","DOI":"10.1002\/14651858.CD003619.pub3"},{"key":"BFsrep23279_CR8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/MD.0b013e3182779d49","volume":"91","author":"ZM Younossi","year":"2012","unstructured":"Younossi, Z. M. et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine 91, 319\u2013327 (2012).","journal-title":"Medicine"},{"key":"BFsrep23279_CR9","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/ajg.2013.104","volume":"108","author":"C Xu","year":"2013","unstructured":"Xu, C. et al. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. Am J Gastroenterol 108, 1299\u20131304 (2013).","journal-title":"Am J Gastroenterol"},{"key":"BFsrep23279_CR10","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/liv.12454","volume":"34","author":"NH Kim","year":"2014","unstructured":"Kim, N. H. et al. Clinical and metabolic factors associated with development and regression of nonalcoholic fatty liver disease in nonobese subjects. Liver Int 34, 604\u2013611 (2014).","journal-title":"Liver Int"},{"key":"BFsrep23279_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.molimm.2014.06.031","volume":"61","author":"E Hertle","year":"2014","unstructured":"Hertle, E., Stehouwer, C. D. & van Greevenbroek, M. M. The complement system in human cardiometabolic disease. Mol Immunol 61, 135\u2013148 (2014).","journal-title":"Mol Immunol"},{"key":"BFsrep23279_CR12","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/hep.23228","volume":"50","author":"SS Rensen","year":"2009","unstructured":"Rensen, S. S. et al. Activation of the complement system in human nonalcoholic fatty liver disease. Hepatology 50, 1809\u20131817 (2009).","journal-title":"Hepatology"},{"key":"BFsrep23279_CR13","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/eci.12093","volume":"43","author":"N Wlazlo","year":"2013","unstructured":"Wlazlo, N. et al. Activated complement factor 3 is associated with liver fat and liver enzymes: the CODAM study. Eur J Clin Invest 43, 679\u2013688 (2013).","journal-title":"Eur J Clin Invest"},{"key":"BFsrep23279_CR14","doi-asserted-by":"publisher","first-page":"e0122026","DOI":"10.1371\/journal.pone.0122026","volume":"10","author":"Q Jia","year":"2015","unstructured":"Jia, Q. et al. Association between Complement C3 and Prevalence of Fatty Liver Disease in an Adult Population: A Cross-Sectional Study from the Tianjin Chronic Low-Grade Systemic Inflammation and Health (TCLSIHealth) Cohort Study. PLoS One 10, e0122026 (2015).","journal-title":"PLoS One"},{"key":"BFsrep23279_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jhep.2011.05.027","volume":"56","author":"C Yu","year":"2012","unstructured":"Yu, C. et al. Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. J Hepatol 56, 241\u2013247 (2012).","journal-title":"J Hepatol"},{"key":"BFsrep23279_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1751-2980.2010.00476.x","volume":"12","author":"JG Fan","year":"2011","unstructured":"Fan, J. G. et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010. J Dig Dis 12, 38\u201344 (2011).","journal-title":"J Dig Dis"},{"key":"BFsrep23279_CR17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","volume":"23","author":"KG Alberti","year":"2006","unstructured":"Alberti, K. G., Zimmet, P. & Shaw, J. Metabolic syndrome\u2013a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 23, 469\u2013480 (2006).","journal-title":"Diabet Med"},{"key":"BFsrep23279_CR18","doi-asserted-by":"publisher","first-page":"d6891","DOI":"10.1136\/bmj.d6891","volume":"343","author":"M Lazo","year":"2011","unstructured":"Lazo, M. et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 343, d6891 (2011).","journal-title":"BMJ"},{"key":"BFsrep23279_CR19","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.cca.2011.03.005","volume":"412","author":"A Onat","year":"2011","unstructured":"Onat, A., Can, G., Rezvani, R. & Cianflone, K. Complement C3 and cleavage products in cardiometabolic risk. Clin Chim Acta 412, 1171\u20131179 (2011).","journal-title":"Clin Chim Acta"},{"key":"BFsrep23279_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.molimm.2015.02.027","volume":"67","author":"A Barbu","year":"2015","unstructured":"Barbu, A., Hamad, O. A., Lind, L., Ekdahl, K. N. & Nilsson, B. The role of complement factor C3 in lipid metabolism. Mol Immunol 67, 101\u2013107 (2015).","journal-title":"Mol Immunol"},{"key":"BFsrep23279_CR21","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1053\/euhj.1999.2013","volume":"21","author":"A Muscari","year":"2000","unstructured":"Muscari, A. et al. Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men. Eur Heart J 21, 1081\u20131090 (2000).","journal-title":"Eur Heart J"},{"key":"BFsrep23279_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1042\/CS20040198","volume":"108","author":"A Onat","year":"2005","unstructured":"Onat, A. et al. Cross-sectional study of complement C3 as a coronary risk factor among men and women. Clin Sci (Lond) 108, 129\u2013135 (2005).","journal-title":"Clin Sci (Lond)"},{"key":"BFsrep23279_CR23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ijcard.2010.09.017","volume":"154","author":"MM van Greevenbroek","year":"2012","unstructured":"van Greevenbroek, M. M. et al. Human plasma complement C3 is independently associated with coronary heart disease, but only in heavy smokers (the CODAM study). Int J Cardiol 154, 158\u2013162 (2012).","journal-title":"Int J Cardiol"},{"key":"BFsrep23279_CR24","doi-asserted-by":"publisher","first-page":"570","DOI":"10.2337\/diabetes.54.2.570","volume":"54","author":"G Engstrom","year":"2005","unstructured":"Engstrom, G., Hedblad, B., Eriksson, K. F., Janzon, L. & Lindgarde, F. Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 54, 570\u2013575 (2005).","journal-title":"Diabetes"},{"key":"BFsrep23279_CR25","doi-asserted-by":"publisher","first-page":"F957","DOI":"10.1152\/ajprenal.00344.2013","volume":"305","author":"X Zhou","year":"2013","unstructured":"Zhou, X. et al. Complement 3 activates the renal renin-angiotensin system by induction of epithelial-to-mesenchymal transition of the nephrotubulus in mice. Am J Physiol Renal Physiol 305, F957\u2013967 (2013).","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFsrep23279_CR26","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1172\/JCI26206","volume":"117","author":"T Vaisar","year":"2007","unstructured":"Vaisar, T. et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 117, 746\u2013756 (2007).","journal-title":"J Clin Invest"},{"key":"BFsrep23279_CR27","doi-asserted-by":"crossref","first-page":"12736","DOI":"10.1016\/S0021-9258(18)42338-1","volume":"267","author":"LN Choy","year":"1992","unstructured":"Choy, L. N., Rosen, B. S. & Spiegelman, B. M. Adipsin and an endogenous pathway of complement from adipose cells. J Biol Chem 267, 12736\u201312741 (1992).","journal-title":"J Biol Chem"},{"key":"BFsrep23279_CR28","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1161\/01.ATV.0000127302.24266.40","volume":"24","author":"L Persson","year":"2004","unstructured":"Persson, L. et al. Lack of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis in apolipoprotein E\u2212\/\u2212 low-density lipoprotein receptor\u2212\/\u2212 mice. Arterioscler Thromb Vasc Biol 24, 1062\u20131067 (2004).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFsrep23279_CR29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrgastro.2010.21","volume":"7","author":"EM Brunt","year":"2010","unstructured":"Brunt, E. M. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 7, 195\u2013203 (2010).","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"BFsrep23279_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3389\/fimmu.2014.00177","volume":"5","author":"R Meli","year":"2014","unstructured":"Meli, R., Mattace Raso, G. & Calignano, A. Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front Immunol 5, 177 (2014).","journal-title":"Front Immunol"},{"key":"BFsrep23279_CR31","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1055\/s-0028-1091980","volume":"28","author":"H Malhi","year":"2008","unstructured":"Malhi, H. & Gores, G. J. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Seminars in liver disease 28, 360 (2008).","journal-title":"Seminars in liver disease"},{"key":"BFsrep23279_CR32","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.194.6.781","volume":"194","author":"CA Ogden","year":"2001","unstructured":"Ogden, C. A. et al. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med 194, 781\u2013795 (2001).","journal-title":"J Exp Med"},{"key":"BFsrep23279_CR33","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/j.1572-0241.2005.40838.x","volume":"100","author":"Z Yesilova","year":"2005","unstructured":"Yesilova, Z. et al. Increased acylation stimulating protein concentrations in nonalcoholic fatty liver disease are associated with insulin resistance. Am J Gastroenterol 100, 842\u2013849 (2005).","journal-title":"Am J Gastroenterol"},{"key":"BFsrep23279_CR34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S0009-9260(05)80350-2","volume":"43","author":"AE Joseph","year":"1991","unstructured":"Joseph, A. E., Saverymuttu, S. H., al-Sam, S., Cook, M. G. & Maxwell, J. D. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 43, 26\u201331 (1991).","journal-title":"Clin Radiol"},{"key":"BFsrep23279_CR35","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMra011775","volume":"346","author":"P Angulo","year":"2002","unstructured":"Angulo, P. Nonalcoholic fatty liver disease. N Engl J Med 346, 1221\u20131231 (2002).","journal-title":"N Engl J Med"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep23279","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep23279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep23279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T12:59:21Z","timestamp":1672837161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep23279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,31]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,9,2]]}},"alternative-id":["BFsrep23279"],"URL":"https:\/\/doi.org\/10.1038\/srep23279","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,31]]},"assertion":[{"value":"29 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23279"}}